Dietary phytochemicals for possible preventive and therapeutic option of uterine fibroids: Signaling pathways as target

A growing interest has emerged on dietary phytochemicals to control diverse pathological conditions. Unfortunately, dietary phytochemical research in uterine fibroids is still under construction. Uterine fibroids/leiomyomas are benign tumors developing from the myometrium of the uterus in premenopausal women. They may occur in more than 70% of women, and approximately 25% of women show clinically significant symptoms. These include heavy and prolonged menstrual bleeding, pelvic pressure (urinary frequency, incontinence, and difficulty with urination), pelvic pain, pelvic mass, infertility, and reproductive dysfunction. Due to lack of medical treatments surgery has been definitive choice for fibroid management. Moreover, surgery negatively affects women’s quality of life, and its associated cost appears to be expensive. The molecular mechanism of fibroids development and growth is not fully elucidated. However, accumulated evidence shows that several signaling pathways, including Smad 2/3, PI3K/AKT/mTOR, ERK 1/2 and β-catenin are involved in the leiomyoma pathogenesis, indicating that they could serve as targets for prevention and/or treatment of this tumor. Therefore, in this review, we discuss the involvement of signaling pathways in leiomyoma development and growth, and introduce some potential dietary phytochemicals that could modulate those signaling pathways. Similar content being viewed by others

Islam MS, Protic O, Stortoni P, Grechi G, Lamanna P, Petraglia F, et al. Complex networks of multiple factors in the pathogenesis of uterine leiomyoma. Fertil Steril 2013;100:178–93. Bulun SE. Uterine fibroids. N Engl J Med 2013;369:1344–55. Day Baird D, Dunson DB, Hill MC, Cousins D, Schectman JM. High cumulative incidence of uterine leiomyoma in black and white women: ultrasound evidence. Am J Obstet Gynecol 2003;188:100–7. Buttram Jr. VC, Reiter RC. Uterine leiomyomata: etiology, symptomatology, and management. Fertil Steril 1981;36:433–45. Sabry M, Al-Hendy A. Innovative oral treatments of uterine leiomyoma. Obstet Gynecol Int 2012;2012:943635. Cardozo ER, Clark AD, Banks NK, Henne MB, Stegmann BJ, Segars JH. The estimated annual cost of uterine leiomyomata in the United States. Am J Obstet Gynecol 2012;206:211 e1–e9. Islam MS, Protic O, Toti P, Giannubilo SR, Tranquilli AL, Petraglia F, et al. Uterine leiomyoma: available medical treatments and new possible therapeutic options. J Clin Endocrinol Metab 2013;98:921–34. Varghese BV, Koohestani F, McWilliams M, Colvin A, Gunewardena S, Kinsey WH, et al. Loss of the repressor REST in uterine fibroids promotes aberrant G protein-coupled receptor 10 expression and activates mammalian target of rapamycin pathway. Proc Natl Acad Sci U S A 2013;110:2187–92. Islam MS, Catherino WH, Protic O, Janjusevic M, Gray PC, Giannubilo SR, et al. Role of activin-A and myostatin and their signaling pathway in human myometrial and leiomyoma cell function. J Clin Endocrinol Metab 2014;99: E775–85. Mesquita FS, Dyer SN, Heinrich DA, Bulun SE, Marsh EE, Nowak RA. Reactive oxygen species mediate mitogenic growth factor signaling pathways in human leiomyoma smooth muscle cells. Biol Reprod 2010;82:341–51. Ono M, Yin P, Navarro A, Moravek MB, Coon JS, Druschitz SA, et al. Paracrine activation of WNT/b-catenin pathway in uterine leiomyoma stem cells promotes tumor growth. Proc Natl Acad Sci U S A 2013;110:17053–8. Sandberg AA. Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors: leiomyoma. Cancer Genet Cytogenet 2005;158:1–26. Mäkinen N, Mehine M, Tolvanen J, Kaasinen E, Li Y, Lehtonen HJ, et al. MED12, the mediator complex subunit 12 gene, is mutated at high frequency in uterine leiomyomas. Science 2011;334:252–5. Kim M-K, Kim K, Han JY, Lim JM, Song YS. Modulation of inflammatory signaling pathways by phytochemicals in ovarian cancer. Genes Nutr 2011;6:109–15. Vidya Priyadarsini R, Nagini S. Cancer chemoprevention by dietary phytochemicals: promises and pitfalls. Curr Pharm Biotechnol 2012;13:125–36. Surh Y-J. Cancer chemoprevention with dietary phytochemicals. Nat Rev Cancer 2003;3:768–80. Chiaffarino F, Parazzini F, La Vecchia C, Chatenoud L, Di Cintio E, Marsico S. Diet and uterine myomas. Obstet Gynecol 1999;94:395–8. Wise LA, Radin RG, Palmer JR, Kumanyika SK, Boggs DA, Rosenberg L. Intake of fruit, vegetables, and carotenoids in relation to risk of uterine leiomyomata. Am J Clin Nutr 2011;94:1620–31. Zhang D, Al-Hendy M, Richard-Davis G, Montgomery-Rice V, Rajaratnam V, Al-Hendy A. Antiproliferative and proapoptotic effects of epigallocatechin gallate on human leiomyoma cells. Fertil Steril 2010;94:1887–93. Zhang D, Al-Hendy M, Richard-Davis G, Montgomery-Rice V, Sharan C, Rajaratnam V, et al. Green tea extract inhibits proliferation of uterine leiomyoma cells in vitro and in nude mice. Am J Obstet Gynecol 2010;202:289 e1–. e9. Malik M, Mendoza M, Payson M, Catherino WH. Curcumin, a nutritional supplement with antineoplastic activity, enhances leiomyoma cell apoptosis and decreases fibronectin expression. Fertil Steril 2009;91:2177–84. Catherino WH, Parrott E, Segars J. Proceedings from the national institute of child health and human development conference on the uterine fibroid research update workshop. Fertil Steril 2011;95:9–12. Wu C-H, Shieh T-M, Wei L-H, Cheng T-F, Chen H-Y, Huang T-C, et al. Resveratrol inhibits proliferation of myometrial and leiomyoma cells and decreases extracellular matrix-associated protein expression. J Funct Foods 2016;23:241–52. Kim D, Ramachandran S, Baek S, Kwon SH, Kwon KY, Cha SD, et al. Induction of growth inhibition and apoptosis in human uterine leiomyoma cells by isoliquiritigenin. Reprod Sci 2008;15:552–8. Moore AB, Castro L, Yu L, Zheng X, Di X, Sifre MI, et al. Stimulatory and inhibitory effects of genistein on human uterine leiomyoma cell proliferation are influenced by the concentration. Hum Reprod 2007;22:2623–31. Islam MS, Akhtar MM, Ciavattini A, Giannubilo SR, Protic O, Janjusevic M, et al. Use of dietary phytochemicals to target inflammation, fibrosis, proliferation, and angiogenesis in uterine tissues: promising options for prevention and treatment of uterine fibroids. Mol Nutr Food Res 2014;58:1667–84. Di X, Andrews DMK, Tucker CJ, Yu L, Moore AB, Zheng X, et al. A high concentration of genistein down-regulates activin A, Smad3 and other TGF-β pathway genes in human uterine leiomyoma cells. Exp Mol Med 2012;44:281–92. Magalhaes B, Peleteiro B, Lunet N. Dietary patterns and colorectal cancer: systematic review and meta-analysis. Eur J Cancer Prev 2012;21:15–23. Aune D, Chan DSM, Vieira AR, Rosenblatt DAN, Vieira R, Greenwood DC, et al. Fruits, vegetables and breast cancer risk: a systematic review and meta-analysis of prospective studies. Breast Cancer Res Treat 2012;134:479–93. Paxton RJ, Garcia-Prieto C, Berglund M, Hernandez M, Hajek RA, Handy B, et al. A randomized parallel-group dietary study for stages II-IV ovarian cancer survivors. Gynecol Oncol 2012;124:410–6. Liu RH. Health-promoting components of fruits and vegetables in the diet. Adv Nutr 2013;4:384S–92S. Giampieri F, Forbes-Hernandez TY, Gasparrini M, Alvarez-Suarez JM, Afrin S, Bompadre S, et al. Strawberry as a health promoter: an evidence based review. Food Funct 2015;6:1386–98. Liu RH. Dietary bioactive compounds and their health implications. J Food Sci 2013;78:A18–25. Amin ARMR, Kucuk O, Khuri FR, Shin DM. Perspectives for cancer prevention with natural compounds. J Clin Oncol 2009;27:2712–25. Shi Y, Hata A, Lo RS, Massagué J, Pavletich NP. A structural basis for mutational inactivation of the tumour suppressor Smad4. Nature 1997;388:87–93. Itoh F, Asao H, Sugamura K, Heldin CH, ten Dijke P, Itoh S. Promoting bone morphogenetic protein signaling through negative regulation of inhibitory Smads. EMBO J 2001;20:4132–42. Xu J, Luo X, Chegini N. Differential expression, regulation, and induction of Smads, transforming growth factor-beta signal transduction pathway in leiomyoma, and myometrial smooth muscle cells and alteration by gonadotropin-releasing hormone analog. J Clin Endocrinol Metab 2003;88:1350–61. Heldin CH, Miyazono K, Ten Dijke P. TGF-β signalling from cell membrane to nucleus through SMAD proteins. Nature 1997;390:465–71. Shi Y, Massagué J. Mechanisms of TGF-β signaling from cell membrane to the nucleus. Cell 2003;113:685–700. Chegini N, Luo X, Ding L, Ripley D. The expression of Smads and transforming growth factor beta receptors in leiomyoma and myometrium and the effect of gonadotropin releasing hormone analogue therapy. Mol Cell Endocrinol 2003;209:9–16. Arici A, Sozen I. Expression, menstrual cycle-dependent activation, and bimodal mitogenic effect of transforming growth factor-beta1 in human myometrium and leiomyoma. Am J Obstet Gynecol 2003;188:76–83. Luo X, Ding L, Xu J, Chegini N. Gene expression profiling of leiomyoma and myometrial smooth muscle cells in response to transforming growth factor-beta. Endocrinology 2005;146:1097–118. Luo X, Ding L, Chegini N. CCNs, fibulin-1C and S100A4 expression in leiomyoma and myometrium: inverse association with TGF-beta and regulation by TGF-beta in leiomyoma and myometrial smooth muscle cells. Mol Hum Reprod 2006;12:245–56. Ding L, Xu J, Luo X, Chegini N. Gonadotropin releasing hormone and transforming growth factor beta activate mitogen-activated protein kinase/ extracellularly regulated kinase and differentially regulate fibronectin, type I collagen, and plasminogen activator inhibitor-1 expression in leiomyoma and myometrial smooth muscle cells. J Clin Endocrinol Metab 2004;89:5549–57. Levens E, Luo X, Ding L, Williams RS, Chegini N. Fibromodulin is expressed in leiomyoma and myometrium and regulated by gonadotropin-releasing hormone analogue therapy and TGF-beta through Smad and MAPK-mediated signalling. Mol Hum Reprod 2005;11:489–94. Laping NJ, Everitt JI, Frazier KS, Burgert M, Portis MJ, Cadacio C, et al. Tumor-specific efficacy of transforming growth factor-beta RI inhibition in Eker rats. Clin Cancer Res 2007;13:3087–99. Ciarmela P, Carrarelli P, Islam MS, Janjusevic M, Zupi E, Tosti C, et al. Ulipristal acetate modulates the expression and functions of activin A in leiomyoma cells. Reprod Sci 2014;21:1120–5. Engelman JA, Luo J, Cantley LC. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet 2006;7:606–19. Ren Y, Yin H, Tian R, Cui L, Zhu Y, Lin W, et al. Different effects of epidermal growth factor on smooth muscle cells derived from human myometrium and from leiomyoma. Fertil Steril 2011;96:1015–20. Zhao L, Vogt PK. Class I PI3K in oncogenic cellular transformation. Oncogene 2008;27:5486–96. Alessi DR, James SR, Downes CP, Holmes AB, Gaffney PRJ, Reese CB, et al. Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Balpha. Curr Biol 1997;7:261–9. Richardson CJ, Schalm SS, Blenis J. PI3-kinase and TOR: PIKTORing cell growth. Semin Cell Dev Biol 2004;15:147–59. Crabtree JS, Jelinsky SA, Harris HA, Choe SE, Cotreau MM, Kimberland ML, et al. Comparison of human and rat uterine leiomyomata: identification of a dysregulated mammalian target of rapamycin pathway. Cancer Res 2009;69:6171–8. Karra L, Shushan A, Ben-Meir A, Rojansky N, Klein BY, Shveiky D, et al. Changes related to phosphatidylinositol 3-kinase/Akt signaling in leiomyomas: possible involvement of glycogen synthase kinase 3alpha and cyclin D2 in the pathophysiology. Fertil Steril 2010;93:2646–51. Kovacs KA, Lengyel F, Vértes Z, Környei JL, Gőcze PM, Sumegi B, et al. Phosphorylation of PTEN (phosphatase and tensin homologue deleted on chromosome ten) protein is enhanced in human fibromyomatous uteri. J Steroid Biochem Mol Biol 2007;103:196–9. Sefton EC, Qiang W, Serna V, Kurita T, Wei J-J, Chakravarti D, et al. MK-2206, an AKT Inhibitor, promotes caspase-independent cell death and inhibits leiomyoma growth. Endocrinology 2013;154:4046–57. Hoekstra AV, Sefton EC, Berry E, Lu Z, Hardt J, Marsh E, et al. Progestins activate the AKT pathway in leiomyoma cells and promote survival. J Clin Endocrinol Metab 2009;94:1768–74. Boulton TG, Nye SH, Robbins DJ, Ip NY, Radzlejewska E, Morgenbesser SD, et al. ERKs: a family of protein-serine/threonine kinases that are activated and tyrosine phosphorylated in response to insulin and NGF. Cell 1991;65:663–75. Yu L, Saile K, Swartz CD, He H, Zheng X, Kissling GE, et al. Differential expression of receptor tyrosine kinases (RTKs) and IGF-I pathway activation in human uterine leiomyomas. Mol Med 2008;14:264–75. Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 2000;103:211–25. Avruch J, Zhang X-f Kyriakis JM. Raf meets Ras: completing the framework of a signal transduction pathway. Trends Biochem Sci 1994;19:279–83. Adachi M, Fukuda M, Nishida E. Nuclear export of MAP kinase (ERK) involves a MAP kinase kinase (MEK)-dependent active transport mechanism. J Cell Biol 2000;148:849–56. Yoon S, Seger R. The extracellular signal-regulated kinase: multiple substrates regulate diverse cellular functions. Growth Factors 2006;24:21–44. Shushan A, Rojansky N, Laufer N, Klein BY, Shlomai Z, Levitzki R, et al. The AG1478 tyrosine kinase inhibitor is an effective suppressor of leiomyoma cell growth. Hum Reprod 2004;19:1957–67. Shushan A, Ben-Bassat H, Mishani E, Laufer N, Klein BY, Rojansky N. Inhibition of leiomyoma cell proliferation in vitro by genistein and the protein tyrosine kinase inhibitor TKS050. Fertil Steril 2007;87:127–35. Liang M, Wang H, Zhang Y, Lu S, Wang Z. Expression and functional analysis of platelet-derived growth factor in uterine leiomyomata. Cancer Biol Ther 2006;5:28–33. Gao Z, Matsuo H, Wang Y, Nakago S, Maruo T. Up-regulation by IGF-I of proliferating cell nuclear antigen and Bcl-2 protein expression in human uterine leiomyoma cells. J Clin Endocrinol Metab 2001;86:5593–9. Moon RT, Kohn AD, De Ferrari GV, Kaykas A. WNT and β-catenin signalling: diseases and therapies. Nat Rev Genet 2004;5:691–701. Logan CY, Nusse R. The Wnt signaling pathway in development and disease. Annu Rev Cell Dev Biol 2004;20:781–810. Mikels AJ, Nusse R. Wnts as ligands: processing, secretion and reception. Oncogene 2006;25:7461–8. Tanwar PS, Lee H-J, Zhang L, Zukerberg LR, Taketo MM, Rueda BR, et al. Constitutive activation of Beta-catenin in uterine stroma and smooth muscle leads to the development of mesenchymal tumors in mice. Biol Reprod 2009;81:545–52. Arango NA, Szotek PP, Manganaro TF, Oliva E, Donahoe PK, Teixeira J. Conditional deletion of beta-catenin in the mesenchyme of the developing mouse uterus results in a switch to adipogenesis in the myometrium. Dev Biol 2005;288:276–83. Markowski DN, Bartnitzke S, Löning T, Drieschner N, Helmke BM, Bullerdiek J. MED12 mutations in uterine fibroids-their relationship to cytogenetic subgroups. Int J Cancer 2012;131:1528–36. Arici A, Sozen I. Transforming growth factor-beta3 is expressed at high levels in leiomyoma where it stimulates fibronectin expression and cell proliferation. Fertil Steril 2000;73:1006–11. Kim S, Xu X, Hecht A, Boyer TG. Mediator is a transducer of Wnt/b-catenin signaling. J Biol Chem 2006;281:14066–75. Jin K-S, Oh YN, Hyun SK, Kwon HJ, Kim BW. Betulinic acid isolated from Vitis amurensis root inhibits 3-isobutyl-1-methylxanthine induced melanogenesis via the regulation of MEK/ERK and PI3K/Akt pathways in B16F10 cells. Food Chem Toxicol 2014;68:38–43. Karna E, Szoka L, Palka JA. Betulinic acid inhibits the expression of hypoxia-inducible factor 1alpha and vascular endothelial growth factor in human endometrial adenocarcinoma cells. Mol Cell Biochem 2010;340:15–20. Viji V, Shobha B, Kavitha SK, Ratheesh M, Kripa K, Helen A. Betulinic acid isolated from Bacopa monniera (L.) Wettst suppresses lipopolysaccharide stimulated interleukin-6 production through modulation of nuclear factor-κB in peripheral blood mononuclear cells. Int Immunopharmacol 2010;10:843–9. Szuster-Ciesielska A, Plewka K, Daniluk J, Kandefer-Szerszeri M. Betulin and betulinic acid attenuate ethanol-induced liver stellate cell activation by inhibiting reactive oxygen species (ROS), cytokine (TNF-α, TGF-β) production and by influencing intracellular signaling. Toxicology 2011;280:152–63. Khan N, Adhami VM, Afaq F, Mukhtar H. Butein induces apoptosis and inhibits prostate tumor growth in vitro and in vivo. Antioxid Redox Signal 2012;16:1195–204. Cho SG, Woo SM, Ko SG. Butein suppresses breast cancer growth by reducing a production of intracellular reactive oxygen species. J Exp Clin Cancer Res 2014;33:51. Zhang L, Chen W, Li X. A novel anticancer effect of butein: Inhibition of invasion through the ERK1/2 and NF-κB signaling pathways in bladder cancer cells. FEBS Lett 2008;582:1821–8. Chung C-H, Chang C-H, Chen S-S, Wang H-H, Yen J-Y, Hsiao C-J, et al. Butein inhibits angiogenesis of human endothelial progenitor cells via the translation dependent signaling pathway. Evid Based Complement Alternat Med 2013;2013:943187. Moon D-O, Choi YH, Moon S-K, Kim W-J, Kim G-Y. Butein suppresses the expression of nuclear factor-kappa B-mediated matrix metalloproteinase-9 and vascular endothelial growth factor in prostate cancer cells. Toxicol in vitro 2010;24:1927–34. Jang JH, Yang ES, Min K-J, Kwon TK. Inhibitory effect of butein on tumor necrosis factor-α-induced expression of cell adhesion molecules in human lung epithelial cells via inhibition of reactive oxygen species generation, NF-Î⍛B activation and Akt phosphorylation. Int J Mol Med 2012;30:1357–64. Lee SD, Choe JW, Lee BJ, Kang MH, Joo MK, Kim JH, et al. Butein effects in colitis and interleukin-6/signal transducer and activator of transcription 3 expression. World Journal of Gastroenterology: WJG 2015;21:465–74. Wang Z, Lee Y, Eun JS, Bae EJ. Inhibition of adipocyte inflammation and macrophage chemotaxis by butein. Eur J Pharmacol 2014;738:40–8. Szuster-Ciesielska A, Mizerska-Dudka M, Daniluk J, Kandefer-Szerszen M. Butein inhibits ethanol-induced activation of liver stellate cells through TGF-β, NFκB, p38, and JNK signaling pathways and inhibition of oxidative stress. J Gastroenterol 2013;48:222–37. Park S-Y, Kim J-Y, Lee S-M, Jun C-H, Cho S-B, Park C-H, et al. Capsaicin induces apoptosis and modulates MAPK signaling in human gastric cancer cells. Mol Med Rep 2014;9:499–502. Lee S-H, Richardson RL, Dashwood RH, Baek SJ. Capsaicin represses transcriptional activity of β-catenin in human colorectal cancer cells. J Nutr Biochem 2012;23:646–55. Min J-K, Han K-Y, Kim E-C, Kim Y-M, Lee S-W, Kim O-H, et al. Capsaicin inhibits in vitro and in vivo angiogenesis. Cancer Res 2004;64:644–51. Bhutani M, Pathak AK, Nair AS, Kunnumakkara AB, Guha S, Sethi G, et al. Capsaicin is a novel blocker of constitutive and interleukin-6 —inducible STAT3 activation. Clin Cancer Res 2007;13:3024–32. Chakraborty S, Adhikary A, Mazumdar M, Mukherjee S, Bhattacharjee P, Guha D, et al. Capsaicin-induced activation of p53-SMAR1 auto-regulatory loop down-regulates VEGF in non-small cell lung cancer to restrain angiogenesis. PLoS One 2014;9:e99743. Bitencourt S, de Mesquita FC, Caberlon E, da Silva GV, Basso BS, Ferreira GA, et al. Capsaicin induces de-differentiation of activated hepatic stellate cell. Biochem Cell Biol 2012;90:683–90. Park J-Y, Kawada T, Han I-S, Kim B-S, Goto T, Takahashi N, et al. Capsaicin inhibits the production of tumor necrosis factor α by LPS-stimulated murine macrophages, RAW 264.7: a PPARγ ligand-like action as a novel mechanism. FEBS Lett 2004;572:266–70. Kim C-S, Kawada T, Kim B-S, Han I-S, Choe S-Y, Kurata T, et al. Capsaicin exhibits anti-inflammatory property by inhibiting IkB-a degradation in LPS-stimulated peritoneal macrophages. Cell Signal 2003;15:299–306. Lim W, Jeong W, Song G. Delphinidin suppresses proliferation and migration of human ovarian clear cell carcinoma cells through blocking AKT and ERK1/2 MAPK signaling pathways. Mol Cell Endocrinol 2016;422:172–81. Pal HC, Sharma S, Strickland LR, Agarwal J, Athar M, Elmets CA, et al. Delphinidin reduces cell proliferation and induces apoptosis of non-small-cell lung cancer cells by targeting EGFR/VEGFR2 signaling pathways. PLoS One 2013;8:e77270. Keravis Trs Favot L, Abusnina AA, Anton A, Justiniano Hln Soleti R, et al. Delphinidin inhibits tumor growth by acting on VEGF signalling in endothelial cells. PLoS One 2015;10:e0145291. Duluc L, Jacques C, Soleti R, Andriantsitohaina R, Simard G. Delphinidin inhibits VEGF induced-mitochondrial biogenesis and Akt activation in endothelial cells. Int J Biochem Cell Biol 2014;53:9–14. Lamy S, Beaulieu E, Labbe D, Bedard V, Moghrabi A, Barrette S, et al. Delphinidin, a dietary anthocyanidin, inhibits platelet-derived growth factor ligand/receptor (PDGF/PDGFR) signaling. Carcinogenesis 2008;29:1033–41. Lim T-G, Jung SK, Kim J-e Kim Y, Lee HJ, Jang TS, et al. NADPH oxidase is a novel target of delphinidin for the inhibition of UVB-induced MMP-1 expression in human dermal fibroblasts. Exp Dermatol 2013;22:428–30. Cho J-S, Kang J-H, Shin J-M, Park I-H, Lee H-M. Inhibitory effect of delphinidin on extracellular matrix production via the MAPK/NF-κB pathway in nasal polyp-derived fibroblasts. Allergy Asthma Immunol Res 2015;7:276–82. Weng JR, Bai LY, Chiu CF, Wang YC, Tsai MH. The dietary phytochemical 3,3′-diindolylmethane induces G2/M arrest and apoptosis in oral squamous cell carcinoma by modulating Akt-NF-κB, MAPK, and p53 signaling. Chem Biol Interact 2012;195:224–30. Rahman KW, Sarkar FH. Inhibition of nuclear translocation of nuclear factor-kB contributes to 3,30-diindolylmethane-induced apoptosis in breast cancer cells. Cancer Res 2005;65:364–71. Zhu J, Li Y, Guan C, Chen Z. Anti-proliferative and pro-apoptotic effects of 3,3′-diindolylmethane in human cervical cancer cells. Oncol Rep 2012;28:1063–8. Leem S-H, Li XJ, Park MH, Park BH, Kim SM. Genome-wide transcriptome analysis reveals inactivation of Wnt/b-catenin by 3, 3′-diindolylmethane inhibiting proliferation of colon cancer cells. Int J Oncol 2015;47:918–26. Kandala PK, Wright SE, Srivastava SK. Blocking epidermal growth factor receptor activation by 3,3′-diindolylmethane suppresses ovarian tumor growth in vitro and in vivo. J Pharmacol Exp Ther 2012;341:24–32. Chang X, Firestone GL, Bjeldanes LF. Inhibition of growth factor-induced Ras signaling in vascular endothelial cells and angiogenesis by 3,3′-diindolylmethane. Carcinogenesis 2006;27:541–50. Kunimasa K, Kobayashi T, Kaji K, Ohta T. Antiangiogenic effects of indole-3-carbinol and 3,3′-diindolylmethane are associated with their differential regulation of ERK1/2 and Akt in tube-forming HUVEC. J Nutr 2010;140:1–6. Kong D, Banerjee S, Huang W, Li Y, Wang Z, Kim H-RC, et al. Mammalian target of rapamycin repression by 3,3′diindolylmethane inhibits invasion and angiogenesis in platelet-derived growth factor-D-overexpressing PC3 cells. Cancer Res 2008;68:1927–34. Kim HW, Kim J, Kim J, Lee S, Choi B-R, Han J-S, et al. 3, 3′-Diindolylmethane inhibits lipopolysaccharide-induced microglial hyperactivation and attenuates brain inflammation. Toxicol Sci 2014;137:158–67. Zhang Z, Gao Z, Hu W, Yin S, Wang C, Zang Y, et al. 3,3′ Diindolylmethane ameliorates experimental hepatic fibrosis via inhibiting miR-21 expression. Br J Pharmacol 2013;170:649–60. Li J, Zhang W, Jiao R, Yang Z, Yuan Y, Wu Q, et al. DIM attenuates TGF-b1-induced myofibroblast differentiation in neonatal rat cardiac fibroblasts. Int J Clin Exp Pathol 2015;8:5121–8. Subramaniam A, Shanmugam MK, Ong TH, Li F, Perumal E, Chen L, et al. Emodin inhibits growth and induces apoptosis in an orthotopic hepatocellular carcinoma model by blocking activation of STAT3. Br J Pharmacol 2013;170:807–21. Pooja T, Karunagaran D. Emodin suppresses Wnt signaling in human colorectal cancer cells SW480 and SW620. Eur J Pharmacol 2014;742:55–64. Way T-D, Huang J-T, Chou C-H, Huang C-H, Yang M-H, Ho C-T. Emodin represses TWIST1-induced epithelial-mesenchymal transitions in head and neck squamous cell carcinoma cells by inhibiting the beta-catenin and Akt pathways. Eur J Cancer 2014;50:366–78. Thacker PC, Karunagaran D. Curcumin and emodin down-regulate TGF-β signaling pathway in human cervical cancer cells. PLoS One 2015;10: e0120045. Kaneshiro T, Morioka T, Inamine M, Kinjo T, Arakaki J, Chiba I, et al. Anthraquinone derivative emodin inhibits tumor-associated angiogenesis through inhibition of extracellular signal-regulated kinase 1/2 phosphorylation. Eur J Pharmacol 2006;553:46–53. Pang X, Liu J, Li Y, Zhao J, Zhang X. Emodin inhibitshomocysteine-induced C-reactive protein generation in vascular smooth muscle cells by regulating PPARg expression and ROS-ERK1/2/p38 signal pathway. PLoS One 2015;10: e0131295. Yin X, Gong X, Jiang R, Kuang G, Wang B, Zhang L, et al. Emodin ameliorated lipopolysaccharide-induced fulminant hepatic failure by blockade of TLR4/MD2 complex expression in D-galactosamine-sensitized mice. Int Immunopharmacol 2014;23:66–72. Li D, Zhang N, Cao Y, Zhang W, Su G, Sun Y, et al. Emodin ameliorates lipopolysaccharide-induced mastitis in mice by inhibiting activation of NF-κB and MAPKs signal pathways. Eur J Pharmacol 2013;705:79–85. Lee J, Jung E, Lee J, Huh S, Hwang C-H, Lee H-Y, et al. Emodin inhibits TNF alpha-induced MMP-1 expression through suppression of activator protein-1 (AP-1). Life Sci 2006;79:2480–5. Wang R, Wan Q, Zhang Y, Huang F, Yu K, Xu D, et al. Emodin suppresses interleukin-1 beta induced mesangial cells proliferation and extracellular matrix production via inhibiting P38 MAPK. Life Sci 2007;80:2481–8. Li X, Liu W, Wang Q, Liu P, Deng Y, Lan T, et al. Emodin suppresses cell proliferation and fibronectin expression via p38MAPK pathway in rat mesangial cells cultured under high glucose. Mol Cell Endocrinol 2009;307:157–62. Ambothi K, Prasad NR, Balupillai A. Ferulic acid inhibits UVB-radiation induced photocarcinogenesis through modulating inflammatory and apoptotic signaling in Swiss albino mice. Food Chem Toxicol 2015;82:72–8. Yang G-W, Jiang J-S, Lu W-Q. Ferulic acid exerts anti-angiogenic and anti-tumor activity by targeting fibroblast growth factor receptor 1-mediated angiogenesis. Int J Mol Sci 2015;16:24011–31. Hou Y, Yang J, Zhao G, Yuan Y. Ferulic acid Inhibits endothelial cell proliferation through NO down-regulating ERK1/2 pathway. J Cell Biochem 2004;93:1203–9. Xu T, Pan Z, Dong M, Yu C, Niu Y. Ferulic acid suppresses activation of hepatic stellate cells through ERK1/2 and Smad signaling pathways in vitro. Biochem Pharmacol 2015;93:49–58. M-g Wei, Sun W, W-m He, Ni L, Yang Y-y. Ferulic acid attenuates TGF-b1-induced renal cellular fibrosis in NRK-52E cells by inhibiting Smad/ILK/Snail pathway. Evid Based Complement Alternat Med 2015;2015:619–720. Kim H-Y, Lee S-M. Ferulic acid attenuates ischemia/reperfusion-induced hepatocyte apoptosis via inhibition of JNK activation. Eur J Pharm Sci 2012;45:708–15. Khan N, Afaq F, Khusro FH, Mustafa AV, Suh Y, Mukhtar H. Dual inhibition of phosphatidylinositol 3-kinase/Akt and mammalian target of rapamycin signaling in human nonsmall cell lung cancer cells by a dietary flavonoid fisetin. Int J Cancer 2012;130:1695–705. Suh Y, Afaq F, Khan N, Johnson JJ, Khusro FH, Mukhtar H. Fisetin induces autophagic cell death through suppression of mTOR signaling pathway in prostate cancer cells. Carcinogenesis 2010;31:1424–33. Zhang X-J, Jia S-S. Fisetin inhibits laryngeal carcinoma through regulation of AKT/NF-kB/mTOR and ERK1/2 signaling pathways. Biomed Pharmacother 2016;83:1164–74. Bhat TA, Nambiar D, Pal A, Agarwal R, Singh RP. Fisetin inhibits various attributes of angiogenesis in vitro and in vivo-implications for angioprevention. Carcinogenesis 2011;33:385–93. Park H-H, Lee S, Oh J-M, Lee M-S, Yoon K-H, Park BH, et al. Anti-inflammatory activity of fisetin in human mast cells (HMC-1). Pharmacol Res 2007;55:31–7. Kim S-C, Kang S-H, Jeong S-J, Kim S-H, Ko HS, Kim S-H. Inhibition of c-Jun N-terminal kinase and nuclear factor kB pathways mediates fisetin-exerted anti-inflammatory activity in lipopolysccharide-treated RAW264.7 cells. Immunopharmacol Immunotoxicol 2012;34:645–50. Lee J-D, Huh J-E, Jeon G, Yang H-R, Woo H-S, Choi D-Y, et al. Flavonol-rich RVHxR from Rhus verniciflua Stokes and its major compound fisetin inhibits inflammation-related cytokines and angiogenic factor in rheumatoid arthritic fibroblast-like synovial cells and in vivo models. Int Immunopharmacol 2009;9:268–76. Kim S-H, Hwang K-A, Choi K-C. Treatment with kaempferol suppressed breast cancer cell growth caused by estrogen and triclosan in cellular and xenograft breast cancer models. J Nutr Biochem 2016;28:70–82. Yao S, Wang X, Li C, Zhao T, Jin H, Fang W. Kaempferol inhibits cell proliferation and glycolysis in esophagus squamous cell carcinoma via targeting EGFR signaling pathway. Tumor Biology 2016;37:10247–56. Dang Q, Song W, Xu D, Ma Y, Li F, Zeng J, et al. Kaempferol suppresses bladder cancer tumor growth by inhibiting cell proliferation and inducing apoptosis. Mol Carcinog 2015;54:831–40. Kim S-Y, Jin Y-R, Lim Y, Kim J-H, Cho M-R, Hong J-T, et al. Inhibition of PDGF beta-receptor tyrosine phosphorylation and its downstream intracellular signal transduction in rat aortic vascular smooth muscle cells by kaempferol. Planta Med 2005;71:599–603. Lee HS, Cho HJ, Kwon GT, Park JHY. Kaempferol downregulates insulin-like growth factor-I receptor and ErbB3 signaling in HT-29 human colon cancer cells. J Cancer Prev 2014;19:161–9. Luo H, Rankin GO, Liu L, Daddysman MK, Jiang B-H, Chen YC. Kaempferol inhibits angiogenesis and VEGF expression through both HIF dependent and independent pathways in human ovarian cancer cells. Nutr Cancer 2009;61:554–63. Mylonis I, Lakka A, Tsakalof A, Simos G. The dietary flavonoid kaempferol effectively inhibits HIF-1 activity and hepatoma cancer cell viability under hypoxic conditions. Biochem Biophys Res Commun 2010;398:74–8. Luo H, Rankin GO, Juliano N, Jiang B-H, Chen YC. Kaempferol inhibits VEGF expression and in vitro angiogenesis through a novel ERK-NFkB-cMyc-p21 pathway. Food Chem 2012;130:321–8. Chen X, Yang X, Liu T, Guan M, Feng X, Dong W, et al. Kaempferol regulates MAPKs and NF-kB signaling pathways to attenuate LPS-induced acute lung injury in mice. Int Immunopharmacol 2012;14:209–16. Suchal K, Malik S, Gamad N, Malhotra RK, Goyal SN, Chaudhary U, et al. Kaempferol attenuates myocardial ischemic injury via inhibition of MAPK signaling pathway in experimental model of myocardial ischemia-reperfusion injury. Oxid Med Cell Longev 2016;2016:7580731. Yoon H-Y, Lee E-G, Lee H, Cho IJ, Choi YJ, Sung M-S, et al. Kaempferol inhibits IL-1b-induced proliferation of rheumatoid arthritis synovial fibroblasts and the production of COX-2, PGE2 and MMPs. Int J Mol Med 2013;32: 971–7. Gong J-H, Cho I-H, Shin D, Han S-Y, Park S-H, Kang Y-H. Inhibition of airway epithelial-to-mesenchymal transition and fibrosis by kaempferol in endotoxin-induced epithelial cells and ovalbumin-sensitized mice. Lab Invest 2013;94:297–308. Jin H, Lee WS, Eun SY, Jung JH, Park H-S, Kim G, et al. Morin, a flavonoid from Moraceae, suppresses growth and invasion of the highly metastatic breast cancer cell line MDA-MB-231 partly through suppression of the Akt pathway. Int J Oncol 2014;45:1629–37. Ma Y, Ge A, Zhu W, Liu Y-N, Ji N-F, Zha W-J, et al. Morin attenuates ovalbumin-induced airway inflammation by modulating oxidative stress-responsive MAPK signaling. Oxid Med Cell Longev 2016;2016:5843672. Dhanasekar C, Kalaiselvan S, Rasool M. Morin, a bioflavonoid suppresses monosodium urate crystal-induced inflammatory immune response in RAW 264. 7 macrophages through the inhibition of inflammatory mediators, intracellular ROS levels and NF-kB activation. PLoS One 2015;10:e0145093. MadanKumar P, NaveenKumar P, Manikandan S, Devaraj H, NiranjaliDevaraj S. Morin ameliorates chemically induced liver fibrosis in vivo and inhibits stellate cell proliferation in vitro by suppressing Wnt/b-catenin signaling. Toxicol Appl Pharmacol 2014;277:210–20. Li H, Yang B, Huang J, Xiang T, Yin X, Wan J, et al. Naringin inhibits growth potential of human triple-negative breast cancer cells by targeting β-catenin signaling pathway. Toxicol Lett 2013;220:219–28. Raha S, Yumnam S, Hong GE, Lee HJ, Saralamma VVG, Park H-S, et al. Naringin induces autophagy-mediated growth inhibition by downregulating the PI3K/Akt/mTOR cascade via activation of MAPK pathways in AGS cancer cells. Int J Oncol 2015;47:1061–9. Zhang Y-S, Li Y, Wang Y, Sun S-Y, Jiang T, Li C, et al. Naringin, a natural dietary compound, prevents intestinal tumorigenesis in Apc Min/+ mouse model. J Cancer Res Clin Oncol 2016;142:913–25. Zeng L, Zhen Y, Chen Y, Zou L, Zhang Y, Hu F, et al. Naringin inhibits growth and induces apoptosis by a mechanism dependent on reduced activation of NF-kB/COX-2-caspase-1 pathway in HeLa cervical cancer cells. Int J Oncol 2014;45:1929–36. Lee E-J, Kim D-I, Kim W-J, Moon S-K. Naringin inhibits matrix metalloproteinase-9 expression and AKT phosphorylation in tumor necrosis factor-alpha-induced vascular smooth muscle cells. Mol Nutr Food Res 2009;53:1582–91. Chen Y, Nie Y-C, Luo Y-L, Lin F, Zheng Y-F, Cheng G-H, et al. Protective effects of naringin against paraquat-induced acute lung injury and pulmonary fibrosis in mice. Food Chem Toxicol 2013;58:133–40. Chen F, Zhang N, Ma X, Huang T, Shao Y, Wu C, et al. Naringin alleviates diabetic kidney disease through inhibiting oxidative stress and inflammatory reaction. PLoS One 2015;10:e0143868. Tsai M-L, Lai C-S, Chang Y-H, Chen W-J, Ho C-T, Pan M-H. Pterostilbene, a natural analogue of resveratrol, potently inhibits 7,12-dimethylbenz [a] anthracene (DMBA)/12-O-tetradecanoylphorbol-13-acetate (TPA)-induced mouse skin carcinogenesis. Food Funct 2012;3:1185–94. Paul S, Rimando AM, Lee HJ, Ji Y, Reddy BS, Suh N. Anti-inflammatory action of pterostilbene is mediated through the p38 mitogen-activated protein kinase pathway in colon cancer cells. Cancer Prev Res (Phila) 2009;2:650–7. Paul S, DeCastro AJ, Lee HJ, Smolarek AK, So JY, Simi B, et al. Dietary intake of pterostilbene, a constituent of blueberries, inhibits the β-catenin/p65 downstream signaling pathway and colon carcinogenesis in rats. Carcinogenesis 2010;31:1272–8. Chiou Y-S, Tsai M-L, Wang Y-J, Cheng A-C, Lai W-M, Badmaev V, et al. Pterostilbene inhibits colorectal aberrant crypt foci (ACF) and colon carcinogenesis via suppression of multiple signal transduction pathways in azoxymethane-treated mice. J Agric Food Chem 2010;58:8833–41. Pan M-H, Chiou Y-S, Chen W-J, Wang J-M, Badmaev V, Ho C-T. Pterostilbene inhibited tumor invasion via suppressing multiple signal transduction pathways in human hepatocellular carcinoma cells. Carcinogenesis 2009;30:1234–42. Zhang Y, Pterostilbene Zhang Y. a novel natural plant conduct, inhibits high fat-induced atherosclerosis inflammation via NF-ÎκB signaling pathway in Toll-like receptor 5 (TLR5) deficient mice. Biomed Pharmacother 2016;81:345–55. Li J, Deng R, Hua X, Zhang L, Lu F, Coursey TG, et al. Blueberry component pterostilbene protects corneal epithelial cells from inflammation via anti-oxidative pathway. Sci Rep 2016;6:19408. Lee MF, Liu ML, Cheng AC, Tsai ML, Ho CT, Liou WS, et al. Pterostilbene inhibits dimethylnitrosamine-induced liver fibrosis in rats. Food Chem 2013;138:802–7. Singh RP, Gu M, Agarwal R. Silibinin inhibits colorectal cancer growth by inhibiting tumor cell proliferation and angiogenesis. Cancer Res 2008;68:2043–50. Ravichandran K, Velmurugan B, Gu M, Singh RP, Agarwal R. Inhibitory effect of silibinin against azoxymethane-induced colon tumorigenesis in A/J mice. Clin Cancer Res 2010;16:4595–606. Raina K, Agarwal C, Agarwal R. Effect of silibinin in human colorectal cancer cells: Targeting the activation of NF-kB signaling. Mol Carcinog 2013;52:195–206. Kim S, Han J, Kim JS, Kim J-H, Choe J-H, Yang J-H, et al. Silibinin suppresses EGFR ligand-induced CD44 expression through inhibition of EGFR activity in breast cancer cells. Anticancer Res 2011;31:3767–73. Lee M-H, Huang Z, Kim DJ, Kim S-H, Kim MO, Lee S-Y, et al. Direct targeting of MEK1/2 and RSK2 by silybin induces cell-cycle arrest and inhibits melanoma cell growth. Cancer Prev Res (Phila) 2013;6:455–65. Lin CH, Li CH, Liao PL, Tse LS, Huang WK, Cheng HW, et al. Silibinin inhibits VEGF secretion and age-related macular degeneration in a hypoxia-dependent manner through the PI-3 kinase/Akt/mTOR pathway. Br J Pharmacol 2013;168:920–31. Garcia-Maceira P, Mateo J. Silibinin inhibits hypoxia-inducible factor-1alpha and mTOR/p70S6K/4E-BP1 signalling pathway in human cervical and hepatoma cancer cells: implications for anticancer therapy. Oncogene 2009;28:313–24. Park J-W, Shin N-R, Shin I-S, Kwon O-K, Kim J-S, Oh S-R, et al. Silibinin inhibits neutrophilic inflammation and mucus secretion induced by cigarette smoke via suppression of ERK-SP1 Pathway. Phytother Res. 2016 Epub ahead of print. Choi YH, Jin GY, Guo HS, Piao HM, Chang Li L, Li GZ, et al. Silibinin attenuates allergic airway inflammation in mice. Biochem Biophys Res Commun 2012;427:450–5. Liu W, Li Y, Zheng X, Zhang K, Du Z. Potent inhibitory effect of silibinin from milk thistle on skin inflammation stimuli by 12-O-tetradecanoylphorbol-13-acetate. Food Funct 2015;6:3712–9. Ai W, Zhang Y, Tang QZ, Yan L, Bian ZY, Liu C, et al. Silibinin attenuates cardiac hypertrophy and fibrosis through blocking EGFR-dependent signaling. J Cell Biochem 2010;110:1111–22. Chen YH, Liang CM, Chen CL, Chen JT, Chang YH, Lu DW, et al. Silibinin inhibits myofibroblast transdifferentiation in human tenon fibroblasts and reduces fibrosis in a rabbit trabeculectomy model. Acta Ophthalmol (Copenh) 2013;97:e506–15. Cho JW, Il KJ, Lee KS. Downregulation of type I collagen expression in silibinin-treated human skin fibroblasts by blocking the activation of Smad2/3-dependent signaling pathways: potential therapeutic use in the chemoprevention of keloids. Int J Mol Med 2013;31:1148–52. Trappoliere M, Caligiuri A, Schmid M, Bertolani C, Failli P, Vizzutti F, et al. Silybin, a component of sylimarin, exerts anti-inflammatory and anti-fibrogenic effects on human hepatic stellate cells. J Hepatol 2009;50:1102–11. Rajput S, Kumar BNP, Dey KK, Pal I, Parekh A, Mandal M. Molecular targeting of Akt by thymoquinone promotes G 1 arrest through translation inhibition of cyclin D1 and induces apoptosis in breast cancer cells. Life Sci 2013;93:783–90. Sutton KM, Greenshields AL, Hoskin DW. Thymoquinone, a bioactive component of black caraway seeds, causes G1 phase cell cycle arrest and apoptosis in triple-negative breast cancer cells with mutant p53. Nutr Cancer 2014;66:408–18. Xu D, Ma Y, Zhao B, Li S, Zhang Y, Pan S, et al. Thymoquinone induces G2/M arrest, inactivates PI3 K/Akt and nuclear factorkB pathways in human cholangiocarcinomas both in vitro and in vivo. Oncol Rep 2014;31:2063–70. Yang J, X-r Kuang, P-t Lv, Yan X-x. Thymoquinone inhibits proliferation and invasion of human nonsmall-cell lung cancer cells via ERK pathway. Tumour Biol 2015;36:259–69. Yi T, Cho S-G, Yi Z, Pang X, Rodriguez M, Wang Y, et al. Thymoquinone inhibits tumor angiogenesis and tumor growth through suppressing AKT and extracellular signal-regulated kinase signaling pathways. Mol Cancer Ther 2008;7:1789–96. Peng L, Liu A, Shen Y, Xu H-Z, Yang S-Z, Ying X-Z, et al. Antitumor and anti-angiogenesis effects of thymoquinone on osteosarcoma through the NF-κB pathway. Oncol Rep 2013;29:571–8. Su X, Ren Y, Yu N, Kong L, Kang J. Thymoquinone inhibits inflammation, neoangiogenesis and vascular remodeling in asthma mice. Int Immunopharmacol 2016;38:70–80. Wang D, Qiao J, Zhao X, Chen T, Guan D. Thymoquinone inhibits IL-1β-induced inflammation in human osteoarthritis chondrocytes by suppressing NF-αB and MAPKs signaling pathway. Inflammation 2015;38:2235–41. Umar S, Hedaya O, Singh AK, Ahmed S. Thymoquinone inhibits TNF-α-induced inflammation and cell adhesion in rheumatoid arthritis synovial fibroblasts by ASK1 regulation. Toxicol Appl Pharmacol 2015;287:299–305. Bai T, Yang Y, Wu Y-L, Jiang S, Lee JJ, Lian L-H, et al. Thymoquinone alleviates thioacetamide-induced hepatic fibrosis and inflammation by activating LKB1-AMPK signaling pathway in mice. Int Immunopharmacol 2014;19:351–7. Bai T, Lian L-H, Wu Y-L, Wan Y, Nan J-X. Thymoquinone attenuates liver fibrosis via PI3K and TLR4 signaling pathways in activated hepatic stellate cells. Int Immunopharmacol 2013;15:275–81. Ghazwani M, Zhang Y, Gao X, Fan J, Li J, Li S. Anti-fibrotic effect of thymoquinone on hepatic stellate cells. Phytomedicine 2013;21:254–60. Pourgholamhossein F, Sharififar F, Rasooli R, Pourgholi L, Nakhaeipour F, Samareh-Fekri H, et al. Thymoquinone effectively alleviates lung fibrosis induced by paraquat herbicide through down-regulation of pro-fibrotic genes and inhibition of oxidative stress. Environ Toxicol Pharmacol 2016;45:340–5. El-Khouly D, El-Bakly WM, Awad A, El-Mesalamy H, El-Demerdash E. Thymoquinone blocks lung injury and fibrosis by attenuating bleomycin-induced oxidative stress and activation of nuclear factor Kappa-B in rats. Toxicology 2012;302:106–13. Author information Authors and Affiliations Corresponding authors Rights and permissions About this article Cite this article Islam, M.S., Segars, J.H., Castellucci, M. et al. Dietary phytochemicals for possible preventive and therapeutic option of uterine fibroids: Signaling pathways as target. Pharmacol. Rep 69, 57–70 (2017). https://doi.org/10.1016/j.pharep.2016.10.013 Received: Revised: Accepted: Published: Issue date: DOI: https://doi.org/10.1016/j.pharep.2016.10.013